RDNT
HealthcareRadNet, Inc. · Medical - Diagnostics & Research · $4B
What is RadNet, Inc.?
RadNet, Inc. is one of the largest operators of outpatient diagnostic imaging centers in the United States. Headquartered in Los Angeles, the company serves patients across multiple states with a broad range of imaging services.
RadNet operates outpatient imaging centers where patients receive scans such as MRI, CT, PET, mammography, and ultrasound without an overnight hospital stay. The company generates revenue primarily through these imaging services, billing insurers and patients directly. Beyond clinical operations, RadNet develops software for the imaging industry — including picture archiving and communication systems — and deploys artificial intelligence tools designed to assist radiologists in detecting conditions such as breast, lung, and prostate cancer.
RadNet was founded in 1997 and is headquartered in Los Angeles, California.
- Outpatient MRI, CT, and PET imaging services
- Mammography and ultrasound diagnostics
- Picture archiving and communication systems (PACS)
- AI-powered cancer detection tools for radiologists
- Multi-modality imaging across regional center networks
Is RDNT a Good Stock to Buy?
UQS Score rates RDNT as Poor overall, reflecting meaningful challenges across several key dimensions of business quality.
The Growth pillar stands out as the clearest positive signal in RadNet's profile. The company has been expanding its center footprint and investing in AI-driven imaging technology, positioning it for continued top-line development in a sector with durable demand.
The Quality, Moat, and Risk pillars all register as Weak, suggesting the underlying business generates limited returns relative to its cost structure and faces competitive and financial pressures. The Valuation pillar reads as Elevated, meaning the current market price does not appear to offer a margin of safety given these weaknesses.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RDNT pay dividends?
No — RadNet, Inc. does not currently pay a dividend.
RadNet does not currently pay a dividend. For a capital-intensive healthcare services operator focused on center expansion and technology investment, retaining cash is a common strategic choice. Investors seeking income from their healthcare allocation will need to look elsewhere, as RDNT's capital is directed toward growth initiatives rather than shareholder distributions.
When does RDNT report earnings?
RadNet reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
RadNet's recent reporting periods have reflected the dual nature of its business — steady demand for imaging services offset by cost pressures typical of operating a large network of physical healthcare facilities. The company's AI and technology segment has drawn investor attention as a potential long-term contributor to margins.
For the most recent quarter's results and guidance, visit RadNet's investor relations page directly.
RDNT Price History
+117.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in RadNet, Inc.?
Based on RadNet, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RDNT Long-term Outlook
RadNet's Growth pillar suggests the business has identifiable expansion levers, particularly through center acquisitions and the commercialization of its AI imaging suite. However, the Weak Risk pillar indicates the path forward carries meaningful execution and financial risk. The Elevated Valuation pillar adds another layer of caution — the current price already reflects optimistic assumptions, leaving limited room for disappointment.
Growth drivers
- Continued outpatient imaging center network expansion across existing and new states
- Commercialization of AI tools for mammography, lung, and prostate cancer detection
- Structural shift of imaging volume from hospitals to lower-cost outpatient settings
Key risks
- High capital requirements for facility operations and technology development
- Reimbursement rate pressure from insurers and government payers
- Elevated valuation leaves limited buffer if growth targets are missed
RDNT vs Peers
RadNet operates in a fragmented healthcare services and diagnostics landscape alongside companies that approach the sector from different angles.
Sotera Health focuses on sterilization and lab testing services for the healthcare supply chain rather than direct patient imaging.
Twist Bioscience operates in synthetic biology and DNA synthesis, a technology-driven segment distinct from RadNet's imaging center model.
BillionToOne develops molecular diagnostic tests, competing in the diagnostics space through a laboratory rather than imaging center model.
Frequently Asked Questions
What does RadNet do?
RadNet operates a network of outpatient diagnostic imaging centers across the United States, offering services such as MRI, CT, PET, mammography, and ultrasound. The company also develops AI-powered tools to help radiologists detect cancers earlier and sells imaging software to the broader healthcare industry.
Does RDNT pay dividends?
No, RadNet does not currently pay a dividend. The company reinvests available capital into expanding its center network and developing its AI and software technology platforms. Income-focused investors should factor this into their evaluation.
When does RDNT report earnings?
RadNet follows a standard quarterly earnings cadence for US-listed companies. Specific dates are not covered by our data source — check RadNet's investor relations page for the current reporting schedule and most recent results.
Is RDNT a good stock to buy?
UQS Score rates RDNT as Poor overall. While the Growth pillar shows promise, the Quality, Moat, and Risk pillars are all Weak, and Valuation reads as Elevated. This combination suggests meaningful risk relative to the current price. The full pillar breakdown is available to Pro members.
Is RDNT overvalued?
The UQS Valuation pillar for RDNT is rated Elevated, indicating the market price appears to reflect optimistic assumptions about future performance. Given the Weak scores in Quality and Risk, the current valuation leaves limited room for execution shortfalls.
How does RDNT compare to its competitors?
RadNet's closest listed peers operate in adjacent healthcare and diagnostics segments rather than direct outpatient imaging. Companies like Sotera Health, Twist Bioscience, and BillionToOne each take different approaches to healthcare services and diagnostics. UQS Pro members can view side-by-side pillar comparisons.
What is RDNT's market cap bracket?
RadNet is classified as a mid-cap company. This places it in a segment of the market that typically offers more growth potential than large-caps but carries more volatility and liquidity risk than mega-cap peers.
Who founded RadNet?
RadNet's founding history is publicly documented and available through the company's official investor relations materials and SEC filings. The company traces its origins to 1997 and is headquartered in Los Angeles, California.
Is RDNT a long-term quality investment?
As a long-term quality indicator, UQS rates RDNT as Poor. The Weak scores in Quality, Moat, and Risk suggest the business has not yet demonstrated the durable competitive advantages and financial resilience typically associated with strong long-term holdings. Growth potential exists, but it comes with elevated risk.
What is the main competitive advantage of RadNet?
RadNet's scale as one of the largest outpatient imaging networks in the US provides some operational leverage. Its investment in proprietary AI tools for cancer detection represents a potential differentiator. However, the UQS Moat pillar currently rates as Weak, suggesting these advantages have not yet translated into durable pricing power or returns.
What sector does RDNT belong to?
RadNet operates in the Healthcare sector, specifically within outpatient diagnostic imaging services. It also has a growing technology segment focused on AI-assisted radiology tools, which adds a software dimension to its otherwise service-heavy business model.
Is RDNT a growth stock or value stock?
Based on its UQS profile, RDNT leans toward growth — the Growth pillar is rated Good, reflecting expansion activity and technology investment. However, the Elevated Valuation pillar means investors are paying a premium for that growth, which is more consistent with a growth-oriented positioning than a value opportunity.
Unlock Full RDNT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare RDNT against sector peers side by side
- ✓Screen for stronger-rated mid-cap healthcare alternatives
- ✓Get the full analyst-style quality and risk assessment
Pro Analysis
RDNT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 28.5 | 4.1 | 30.0 | 63.1 | 9.4 | 39.7 | -0.1 |
| May 7, 2026 | 28.6 | 3.2 | 30.0 | 63.1 | 15.9 | 35.7 | -0.1 |
| May 3, 2026 | 28.7 | 3.2 | 30.0 | 63.1 | 15.9 | 36.3 | 0.0 |
| Apr 26, 2026 | 28.7 | 3.2 | 30.0 | 63.1 | 15.9 | 36.1 | +0.2 |
| Apr 21, 2026 | 28.5 | 3.2 | 30.0 | 63.1 | 15.9 | 34.6 | 0.0 |
| Apr 19, 2026 | 28.5 | 3.2 | 30.0 | 63.1 | 15.9 | 34.5 | -0.4 |
| Apr 18, 2026 | 28.9 | 3.2 | 30.0 | 63.1 | 15.9 | 37.1 | -1.2 |
| Apr 14, 2026 | 30.1 | 3.2 | 30.0 | 63.1 | 15.9 | 45.2 | -0.1 |
| Apr 12, 2026 | 30.2 | 3.2 | 30.0 | 63.1 | 15.9 | 45.7 | 0.0 |
| Apr 4, 2026 | 30.2 | 3.2 | 30.0 | 63.1 | 15.9 | 46.1 | +0.1 |
RDNT — Pillar Breakdown
Quality
— 4.1/100 (25%)RadNet, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 63.1/100 (20%)RadNet, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 9.4/100 (15%)RadNet, Inc. presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 39.7/100 (15%)RadNet, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 30/100 (25%)RadNet, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RDNT.
Score Composition
Financial Data
More Stock Analysis
How is the RDNT UQS Score Calculated?
The UQS (Unified Quality Score) for RadNet, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses RadNet, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether RadNet, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.